Fibrinolytic and antithrombotic regimens in recently completed, ongoing and planned clinical trials in myocardial infarction

Bibliography

• RYAN TJ, ANDERSON JL, ANTMAN EM et al.: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on management of acute myocardial infarction). J. Am. Coll. Cardiol (1996) 28:1328–1428.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive evidence-based review of the managementof acute myocardial infarction.
   Google Scholar
• FIBRINOLYTIC THERAPY TRIALISTS' (FTT) COLLABORA- TIVE GROUP: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet (1994) 343:311–322.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive overview of all major randomised fibrino-lytic trials in myocardial infarction up to 1994.
   Google Scholar
• THE GUSTO INVESTIGATORS: An international randomized trial comparing four thrombolytic strate-gies for acute myocardial infarction. New Engl. J. Med. (1993) 329:673–682.
   PubMed Web of Science ®Google Scholar
• •Historical trial that established the superiority of t-PA over streptokinase for thrombolysis in acute myocardial infarction.
   Google Scholar
• COLLEN D, BERNAERTS R, DECLERCK P et al.: Recombi- nant staphylokinase variants with altered immunore-activity. I: Construction and characterization. Circulation (1996) 94:197–206.
   PubMed Web of Science ®Google Scholar
• VANDERSCHUEREN S, DENS J, KERDSINCHAI P et al. A randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am. Heart J. (1997) 134(2 Pt 1):213–9.
   Google Scholar
• THE CANADIAN AND BELGIUM STAPHYLOKINASE ANGIOGRAPHIC INVESTIGATORS: A dose-finding angiographic patency trial to establish the compara-tive thrombolytic efficacy and safety of recombinant staphylokinase (SAK42D). The Canadian VIGOUR/EPICORE Centre (1997). Unpublished study protocol.
   Google Scholar
• COLLER BS, SCUDDER LR: Inhibition of dog platelet function by in vivo infusion of F(all')2 fragments of a monoclonal antibody to the platelet glycoprotein Ilb/Ifia receptor. Blood (1985) 66:1456–1459.
   PubMed Web of Science ®Google Scholar
• VERHEUGT FWA, OHMAN EM, ANTMAN EM et al: Emergency room infusion of abciximab speeds up reperfusion in acute myocardial infarction eligible for primary PTCA. J. Am. Coll Cardiol (1999) 33:354A.
   Google Scholar
• GUSTO IV AMI: A phase III, randomized, open-label trial evaluating the efficacy and safety of ReoPro (abciximab) in combination with reduced dose Retavase/Rapilysin (recombinant plasminogen activator, reteplase, r-PA) for the treatment of acute myocardial infarction. Centocor, Inc. (1999). Unpublished study protocol.
   Google Scholar
• MARAGANORE JM: Preclinical and clinical studies on hirulog: a potent and specific direct thrombin inhibitor. In: Design of synthetic inhibitors of thrombin. Claeson G, Scully MF, Kakkar VV, Deadman J (Eds.). Plenum Press, New York (1993):227–236.
   Google Scholar
• WEITZ JI, HUDOBA M, MASSEL D et al.: Clot-bound thrombin Is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. (1990) 86:385–391.
   PubMed Web of Science ®Google Scholar
• WEBSTER MWI, CHESEBRO JH, FUSTER V: Antithrom-botic therapy in acute myocardial infarction: enhance-ment of thrombolysis, reduction of reocclusion, and prevention of thromboembolism. In: Acute myocardial infarction. Gersh BJ, Rahimtoola SH (Eds.). Elsevier Science Publishing Co. Inc., New York (1990:333–348.
   Google Scholar
• THE GLOBAL USE OF STRATEGIES TO OPEN OCCLUDEDCORONARY ARTERIES (GUSTO) IIB INVESTIGATORS: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome. New Engl. J. Med. (1996) 335:775–782.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, FOR THE TIMIT 9B INVESTIGATORS: Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMO 9B trial. Circulation (1996) 94:911–921.
   PubMed Web of Science ®Google Scholar
• WHITE HD, AYLWARD PE, FREY MJ, ET AL., FOR THEHIRULOG EARLY REPERFUSION/OCCLUSION (HERO) TRIAL INVESTIGATORS: Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocar-dial infarction (HERO). Circulation (1997) 96:2155–2161.
   PubMed Web of Science ®Google Scholar
• WHITE HD: Direct thrombin inhibition and thrombolytic therapy: Rationale for the hirulog and early reperfusion/occlusion (HERO-2) trial. Am. J. Cardiol. (1998) 82:57P–62P.
   Google Scholar
• ALEXANDER JH, HARRINGTON RA: Antiplatelet and antithrombin therapies in the acute coronary syndromes. Curr. Opin. Cardiol. (1997) 12:427–437.
   PubMed Web of Science ®Google Scholar
• •Excellent overview of the roles of contemporary antiplate-lets and antithrombotics in acute coronary syndrome.
   Google Scholar
• PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT (PRISM) STUDY INVESTIGA-TORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl. J. Med. (1998) 338:1498–1505.
   PubMed Web of Science ®Google Scholar
• PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT IN PATIENTS LIMITED TO UNSTABLE SIGNS AND SYMPTOMS (PRISM-PLUS) STUDY INVESTIGATORS: Inhibition of the platelet glycopro-teinilb/Illa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl. J. Med. (1998) 338:1488–1497.
   PubMed Web of Science ®Google Scholar
• PLATELET GLYCOPROTEIN IIB/IIIA IN UNSTABLE ANGINA: RECEPTOR SUPPRESSION USING INTEGRILIN THERAPY (PURSUIT) TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein Ilb/Illa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. New Engl. J. Med. (1998) 339:436–443.
   PubMed Web of Science ®Google Scholar
• GUSTO IV ACS: A phase III, randomized, double-blind placebo-controlled trial evaluating the efficacy and safety of ReoPro given as a bolus followed by a 24- or 48-hour infusion, for the treatment of acute coronary syndrome without ST-segment elevation. Centocor, Inc. (1997). Unpublished study protocol.
   Google Scholar
• Investigational drug brochure lamifiban. Hoffmann-La Roche Ltd. (1997).
   Google Scholar
• PARAGON INVESTIGATORS: International, random-ized, controlled trial of lamifiban (a platelet glycopro-tein Ilb/Illa inhibitor), heparin or both in unstable angina. Circulation (1998) 97:2386–2395.
   PubMed Web of Science ®Google Scholar
• PARAGON B: A randomized, double-blind, placebo-controlled study of lamifiban (Ro 44–9883) in patients with unstable angina / non-Q-wave myocardial infarc-tion. Hoffmann-La Roche Ltd. (1998). Unpublished study protocol.
   Google Scholar
• HARRINGTON RA, GRAFFAGNINO C, ARMSTRONG PW, ET AL., APLAUD INVESTIGATORS: Inhibitor, SB 214857, in patients with coronary artery and cerebrovascular disease: The APLAUD results. Circulation (1998) 98:1–251.
   PubMedGoogle Scholar
• DMP 754–010: A phase II, randomized, double-blind, multicenter, acetylsalicylic acid-controlled, multi-dose study of DMP 754 alone or in combination with aspirin in patients with coronary artery disease. DuPont Pharmaceuticals Company (1998). Unpublished study protocol.
   Google Scholar
• DMP 754–017: A phase II, randomized, open-label, crossover, multicenter, multi-dose study of the safety, pharmacokinetics, and pharmacodynamics of DMP 754 (roxifiban) in combination with aspirin in patients with coronary artery disease. DuPont Pharma-ceuticals Company (1998). Unpublished study protocol.
   Google Scholar
• TOPOL EJ, CALIFF R, VAN DE WERF F et al. THE SYMPHONY TRIAL: A phase III, multicenter, interna-tional, randomized, double-blind, aspirin-controlled trial to evaluate the efficacy and safety of sibrafiban (Ro 48–3657), an oral platelet glycoprotein Hb/IIIa antagonist, as therapy for the prevention of secondary vascular events in patients after an acute coronary syndrome. Hoffmann-La Roche Inc. (1997). Unpublished study protocol.
   Google Scholar
• TOPOL EJ, CALIFF R, VAN DE WERF F et al., THE 2ND SYMPHONY TRIAL: A phase III, multicenter, interna-tional, randomized, double-blind, aspirin-controlled trial to evaluate the efficacy and safety of two regimens with Xubix (sibrafiban; Ro 48–3657), an oral platelet glycoprotein Ilb/Illa antagonist, as therapy for the long term prevention of secondary vascular events in patients after an acute coronary syndrome. Hoffmann-La Roche Inc. (1998). Unpublished study protocol.
   Google Scholar
• WEITZ JI: Drug therapy: Low-molecular-weight heparins. New Engl. J. Med. (1997) 337:688–698.
   PubMed Web of Science ®Google Scholar
• •Excellent overview on the mechanism of action of low-molecular-weight heparins and of their use in acute coronary syndrome
   Google Scholar
• WALLENTIN L, HUSTED S, KONTNY F et al. FOR THE FRISC II STUDY GROUP: Long-term low-molecular-weight heparin (Fragmin) and / or early revascularization during instability in coronary artery disease (the FRISC II study). Am. J. Cardiol. (1997) 80(5A):61E–63E.
   Google Scholar
• THE GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES (GUSTO) IIA INVESTIGATORS: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. (1994) 90:1631–1637.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM: Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIIVID 9A trial. Circulation (1994) 90:1624–1630.
   Google Scholar
• ORGANIZATION TO ASSESS STRATEGIES FOR ISCHEMIC SYNDROMES (OASIS-2) INVESTIGATORS: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomized trial. Lancet. (1999) 353:429–438.
   PubMed Web of Science ®Google Scholar
• Product: PEG-Hirudin. Investigator's Brochure. Knoll Phama Inc. (1998):8–18.
   Google Scholar
• LEVITSKY J, GURELL D, FRISHMAN WH: Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. J. Clin. Pharmacol. (1998) 38:887–897.
   PubMed Web of Science ®Google Scholar
• SCHOLZ W, ALBUS U, COUNILLON L et al.: Protective effects of 110E642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischemia and reperfusion. Cardiovasc. Res. (1995) 29:260–268.
   PubMed Web of Science ®Google Scholar